BioSpace News Archive

Soin Therapeutics, a pharmaceutical company based in Dayton, OH, was granted orphan drug status from the FDA for low dose naltrexone to treat complex regional pain syndrome.

ITM AG, a leading radiopharmaceutical company, announced that it will host a virtual industry satellite symposium titled, “A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy” at the European Society of Medical Oncology Congress 2021.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that John Bencich, Chief Executive Officer, will be participating in two upcoming investor conferences.

More than 7 million Canadians suffer from immune-mediated inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and related conditions.

PAQ Therapeutics, a biotechnology company harnessing the power of autophagy to restore health and cure disease, and Insilico Medicine, an end-to-end artificial intelligence -driven drug discovery company, announced that the companies have entered into a collaboration agreement to develop small molecule therapies designed to hijack the autophagy pathway to address novel disease targets.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, provides updates on recent and upcoming developments.

SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced a paper, titled “A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2,” is available on medRxiv.

Neuroglee announced today that it has closed a $10 million Series A funding round.

Immuneering Corporation, a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, updated its financial outlook for full year 2021.